← Back to Search

Monoclonal Antibodies

A Phase I Study of LY3471851 in Healthy Participants

Phase 1
Waitlist Available
Research Sponsored by Nektar Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up predose up to 56 days postdose

Summary

This trial will compare the absorption and removal of two different formulations of LY3471851 in healthy participants, as well as any potential side effects. Participants will receive the study drug for 12 weeks.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~predose up to 56 days postdose
This trial's timeline: 3 weeks for screening, Varies for treatment, and predose up to 56 days postdose for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
PK: Area Under the Concentration Versus Time Curve (AUC) of LY3471851
Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3471851

Trial Design

4Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: LY3471851 (Test) + LevocetirizineExperimental Treatment2 Interventions
LY3471851 administered SC in combination with levocetirizine given orally.
Group II: LY3471851 (Test formulation)Experimental Treatment1 Intervention
LY3471851 administered subcutaneously (SC).
Group III: LY3471851 (Reference formulation)Active Control1 Intervention
LY3471851 administered SC.
Group IV: PlaceboPlacebo Group1 Intervention
Placebo administered SC.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LY3471851
2021
Completed Phase 2
~670
Levocetirizine
2012
Completed Phase 4
~14570

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Nektar TherapeuticsLead Sponsor
58 Previous Clinical Trials
10,275 Total Patients Enrolled
Eli Lilly and CompanyIndustry Sponsor
2,679 Previous Clinical Trials
3,465,712 Total Patients Enrolled
Study DirectorStudy DirectorNektar Therapeutics
1,281 Previous Clinical Trials
500,461 Total Patients Enrolled
Study DirectorEli Lilly and Company
1,389 Previous Clinical Trials
428,127 Total Patients Enrolled
~13 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top